Ovid Therapeutics Inc. (OVID) Stock Price & Analysis
Ovid Therapeutics Inc. (OVID) rose 0.72% to USD 2.8 as of September 8, 2026 at 07:36 UTC, according to Nexqual real-time market data.
OVID last closed at USD 2.8; the session ranged USD 2.71–2.83 on volume of 1,066,037 shares. Market capitalization is —, with a 52-week range of USD 1.12–3.11 (NCM). Source: Nexqual, September 8, 2026 at 07:36 UTC.
Key Statistics (as of September 8, 2026 at 07:36 UTC)
| Price | USD 2.8 |
|---|---|
| Change | ▲ 0.72% (up) |
| Previous Close | USD 2.8 |
| Open | USD 2.8 |
| Day Range | USD 2.71 – 2.83 |
| 52-Week Range | USD 1.12 – 3.11 |
| Volume | 1,066,037 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (OVID)
Nexqual's technical model rates OVID "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 07:36 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.15 (neutral) |
| vs SMA50 | Above (USD 2.61) |
| MACD | 0.06 (positive) |
From Ovid Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Unmet need in epilepsy Approximately 50 million people globally live with epilepsy, including an estimated three million adults and half a million children in the United States.
- Today, we are one of the few companies that has researched and developed three distinct MoAs to target seizures and we believe we are the only company that holds a portfolio of direct activators of KCC2.
- Intellectual Property Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our current and future drug candidates, novel discoveries, product development technologies and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing upon our proprietary rights.
- We also rely on trademarks, trade secrets, copyright protection, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.
Partnerships
- We also entered into a collaboration agreement with Gensaic (the "Gensaic Collaboration Agreement") to potentially develop up to three genetic medicines for neurological indications of interest to us, harnessing Gensaic's proprietary tissue-selective intracellular delivery platform.
- Exclusive In-Licensing Agreement with AstraZeneca (2021) In December 2021, we entered into an exclusive license agreement ("AstraZeneca Exclusive License Agreement") with AstraZeneca.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc. | USD 4.04 | ▲ 0% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.71 | ▼ 0.27% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 14.39 | ▲ 1.34% |
| ASMB | Assembly Biosciences, Inc. | USD 36.6 | ▼ 0.33% |
| KALA | KALA BIO, Inc. | USD 0.51 | ▼ 3.06% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:36 UTC. This page is informational and not investment advice.